Senti up as pre-clinical data from lead cancer therapy shows promise

Senti Biosciences Holdings

12/12/2022 12:27

** Shares of cancer therapies developer Senti Biosciences
Inc  SNTI.O  rise 7.5% at $2.2 in premarket trading
    ** SNTI reports positive pre-clinical data from cell therapy
SENTI-202 and selects it as co's lead cancer treatment candidate
    ** SENTI-202 showed significant and precise cancer-killing
activity in treating acute myeloid leukemia (AML) and
myelodysplastic syndrome (MDS)  - SNTI
    **  Both AML and MDS are groups of cancers associated with
the blood and bone marrow 
    ** Co adds cell therapy also showed protection of healthy
cells from off-tumor cytotoxicity, that refers to the ability of
certain chemicals or mediator cells to destroy living cells 
    ** SNTI plans to evaluate SENTI-202 in patients with
hematologic malignancies, and anticipates to submit 
Investigational New Drug application to FDA in H2 of 2023
    ** YTD, stock down 79.6%, as of Friday's close
 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))